An open-label, multi-center protocol to provide QTI571 to PAH patients who participated in one of the extension studies and are judged by the investigator to benefit from continued QTI571 treatment
Latest Information Update: 17 Dec 2013
At a glance
- Drugs Imatinib (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 04 Dec 2013 New trial record